MYE0 logo

MaxCyte DB:MYE0 Stock Report

Last Price

€3.78

Market Cap

€416.7m

7D

-6.4%

1Y

-6.9%

Updated

25 Dec, 2024

Data

Company Financials +

MaxCyte, Inc.

DB:MYE0 Stock Report

Market Cap: €416.7m

MYE0 Stock Overview

A life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. More details

MYE0 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Rewards

Revenue is forecast to grow 21.32% per year

Risk Analysis

Currently unprofitable and not forecast to become profitable over the next 3 years

Volatile share price over the past 3 months compared to the German market


My Notes

Capture your thoughts, links and company narrative

MaxCyte, Inc. Competitors

Evotec

XTRA:EVT

€1.5b

Gerresheimer

XTRA:GXI

€2.4b

SCHOTT Pharma KGaA

XTRA:1SXP

€3.7b

Sartorius

XTRA:SRT3

€13.5b

Price History & Performance

Summary of share price highs, lows and changes for MaxCyte
Historical stock prices
Current Share PriceUK£3.78
52 Week HighUK£4.96
52 Week LowUK£2.98
Beta1.16
1 Month Change19.62%
3 Month Change14.55%
1 Year Change-6.90%
3 Year Change-58.69%
5 Year Changen/a
Change since IPO-48.57%

Recent News & Updates

Recent updates

Shareholder Returns

MYE0DE Life SciencesDE Market
7D-6.4%-1.4%-1.6%
1Y-6.9%-5.5%6.8%

Return vs Industry: MYE0 underperformed the German Life Sciences industry which returned -5.6% over the past year.

Return vs Market: MYE0 underperformed the German Market which returned 6.8% over the past year.

Price Volatility

Is MYE0's price volatile compared to industry and market?
MYE0 volatility
MYE0 Average Weekly Movement8.2%
Life Sciences Industry Average Movement7.1%
Market Average Movement4.9%
10% most volatile stocks in DE Market11.6%
10% least volatile stocks in DE Market2.4%

Stable Share Price: MYE0's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: MYE0's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
1998143Maher Masoudwww.maxcyte.com

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols.

MaxCyte, Inc. Fundamentals Summary

How do MaxCyte's earnings and revenue compare to its market cap?
MYE0 fundamental statistics
Market cap€416.74m
Earnings (TTM)-€34.37m
Revenue (TTM)€43.86m

9.5x

P/S Ratio

-12.1x

P/E Ratio

Is MYE0 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
MYE0 income statement (TTM)
RevenueUS$45.60m
Cost of RevenueUS$6.39m
Gross ProfitUS$39.21m
Other ExpensesUS$74.94m
Earnings-US$35.74m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.34
Gross Margin85.98%
Net Profit Margin-78.37%
Debt/Equity Ratio0%

How did MYE0 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 07:47
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

MaxCyte, Inc. is covered by 11 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Mark MassaroBTIG
Matthew HewittCraig-Hallum Capital Group LLC
Paul CuddonNumis Securities Ltd.